Zenith Drugs EV/EBITDA Ratio

Zenith Drugs Ltd Enterprise Value to EBITDA Ratio

The Zenith Drugs Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Zenith Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Zenith Drugs Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Zenith Drugs Ltd (NSE: ZENITHDRUG, BSE: 92356) is currently trading at ₹39.95, with a market capitalization of ₹653.37M. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Zenith Drugs Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.

Zenith Drugs Ltd Enterprise Value to EBITDA Ratio Current Value

The current Zenith Drugs Ltd Enterprise Value to EBITDA Ratio stands at 0.

The Zenith Drugs Ltd Enterprise Value to EBITDA Ratio remains stable, indicating consistent financial performance.

Zenith Drugs Ltd Enterprise Value to EBITDA Ratio Historical Trend

The Zenith Drugs Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Zenith Drugs Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.

What Zenith Drugs Ltd Enterprise Value to EBITDA Ratio Indicates for Investors

The Zenith Drugs Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.

This ratio is an important metric used in fundamental analysis of Zenith Drugs Ltd.

Zenith Drugs Ltd Enterprise Value to EBITDA Ratio Analysis Summary

The Zenith Drugs Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Zenith Drugs Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Zenith Drugs Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.